Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 124Multiple Myeloma 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 76Lymphoma 73Lymphoma, Non-Hodgkin 66Leukemia 66Myelodysplastic Syndromes 56Hodgkin Disease 53Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Mantle-Cell 33Breast Neoplasms 32Neuroblastoma 30Leukemia, Lymphocytic, Chronic, B-Cell 30Burkitt Lymphoma 30Lymphoma, Follicular 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Recurrence 24Sarcoma 18Neoplasms, Plasma Cell 18Hematologic Neoplasms 18Central Nervous System Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Leukemia, Biphenotypic, Acute 16Myeloproliferative Disorders 15Lymphoma, Large-Cell, Immunoblastic 15Congenital Abnormalities 15Brain Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Anemia, Refractory, with Excess of Blasts 13Medulloblastoma 12

Interventions

sargramostim 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Transplant-Related Hematologic Malignancy × Granulocyte Colony-Stimulating Factor × Clear all
NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Northside Hospital, Inc.

Phase 2 Recruiting
38 enrolled

Transplant-Related Hematologic Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡